Rosa Visits 2 - 3: A 51-year-old woman requiring additional lipid-lowering therapy


Rosa Visits 2 - 3: A 51-year-old woman requiring additional lipid-lowering therapy

Topic: Cardiology
Relevant Terms: CAD, Dyslipidemia, Obesity, Abdominal Obesity, Hypertension
Primary Audience: Physicians; Physician Assistants; Pharmacists; Registered Nurses; Nurse Practitioners with an interest in lipid management
Launch Date: 04-Oct-12
Credits: 0.5 AMA PRA Category 1 Credit
0.5 ACPE contact hour
0.5 ANCC contact hour
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Optimizing lipid-lowering therapy

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Demonstrate improvement in getting patients to lipid goals aligned with performance indicators
  2. Implement strategies for the entire patient care team to improve patient adherence to lipid-modifying therapies
  3. Identify the frequency and secondary causes of statin intolerance and treatment options for statin-intolerant patients
  4. Identify contributing factors and implications of nonadherence to lipid-lowering therapies in light of recent findings, and with a focus on recognizing cultural disparities
  5. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families


    James Underberg, MD, MS, FACPM, FACP, FNLA
    Clinical Assistant Professor of Medicine 
    NYU Medical School 
    Director, Primary Care Lipid Management Clinic
    Bellevue Hospital Lipid Clinic
    New York, New York
    Lynne Braun, PhD, CNP, FAHA, FNLA
    Professor of Nursing and Nurse Practitioner
    Rush University Medical Center
    Chicago, IL
    David T. Nash, MD, MBA, FNLA*
    Syracuse Preventive Cardiology
    Syracuse, NY
    Program Format: Enduring Internet
    There is no fee associated with this activity.
    Statement of Need
    Clinicians face numerous clinical challenges, including remaining abreast of new and important clinical information that may potentially impact current treatment decisions. Recent debate has focused on best practices for improving health care outcomes for the patient at risk for CVD. Studies have explored increasing the population benefits of statins by lowering the thresholds for treatment. However, recent data suggest that a strategy to improve adherence to statins among the highest-risk patients would prevent twice as many additional deaths as a strategy to widen prescribing by lowering treatment thresholds. Recent studies also raise concern that policy-driven statin substitution may cause disruption in adherence to treatment and negatively impact attainment of NCEP ATP III goals.
    Target Audience
    This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners with an interest in lipid management.

      CME credit provided by the National Lipid Association
    The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Lipid Association designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
    Postgraduate Institute for Medicine


    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Universal Activity Number – 0809-9999-12-327-H01-P (knowledge)
    Postgraduate Institute for Medicine designates this continuing education activity for .5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
    This educational activity for .5 contact hour is provided by Postgraduate Institute for Medicine.
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
    Criteria for Success
    Statements of credit will be awarded based on the participant's successful completion of the post-test with a score of 70% or better and the activity evaluation. If you have questions about this CME/CE activity, please contact the NLA at

    Estimated time of completion: 30 minutes.
    Faculty Disclosures
    Lynne T. Braun, PhD, CNP, FAHA, FNLA
    Advisory Board: UpToDate, Inc.
    Royalty: UpToDate, Inc.
    Contracted Research: National Health Institute
    David T. Nash, MD, MBA, FNLA
    Nothing to Disclose

    James Underberg, MD, MS, FACPM, FACP, FNLA:

    Advisory Board: Abbott Laboratories; GlaxoSmithKline; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.
    Consultant: LipoScience, Inc.; Genzyme; News Corporation; Publicis, Inc.; Guidepoint Global
    Speakers Bureau:  Abbott Laboratories; Forest Pharmaceuticals; GlaxoSmithKline; Daiichi Sankyo, Inc.; Kowa Pharmaceuticals America, Inc.; Pfizer, Inc.; LipoScience, Inc.; diaDexus, Inc.; Merck & Co., Inc.; Eli Lilly & Co., AstraZeneca, GlaxoSmithKline, Liposcience, Takeda, Merck-ScheringPlough
    Planners Disclosures
    NLA and PIM staff planners and reviewers have no relevant financial relationships to disclose.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Disclosure Declaration
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.
    Copyright 2012, by the National Lipid Association, Jacksonville, FL. All rights reserved.
    System Requirements
    To view this educational activity you will need one of the following web browsers: Google Chrome for Windows, Mac, or Linux; Internet Explorer 7.0+ for Windows; Mozilla 1.4+ for Windows, Mac, or Linux; Firefox 3.5+ for Windows, Mac, or Linux; or Safari 4.0+ for Mac.

    Commercial Support
    This continuing education activity is supported by educational grants from Abbott Laboratories and Daiichi Sankyo Inc.